Ben David SS, Potasman I, Rahamim-Cohen D, et al. - Researchers sought to determine whether rates of Guillain-Barré Syndrome (GBS) relapse are higher among Pfizer-BioNTech BNT162b2 vaccine receivers.

• Researchers performed a descriptive retrospective cohort study in the second largest health maintenance organization in Israel, Maccabi Healthcare Services (MHS), and identified data of 702 cases of GBS between 2000 and 2020 [48% women; mean (SD) age 53 (18) years].

• Of these patients, 579 and 539 had received 1 and 2 doses, respectively.

• Short medical care was required by only 1 patient for relapse of previous syndrome, which represents a minimal risk.

• Based on findings, researchers support the Israeli Ministry of Health and national immunization guidelines that did not include a history of GBS as a precaution or contraindication to receiving the COVID-19 vaccine.